ALL Metrics
-
Views
-
Downloads
Get PDF
Get XML
Cite
Export
Track
Systematic Review

The Association between Early-Onset Pancreatic Ductal Adenocarcinoma and Patients Survival: A Systematic Review and Meta-Analysis

[version 1; peer review: 2 approved]
PUBLISHED 28 Aug 2024
Author details Author details
OPEN PEER REVIEW
REVIEWER STATUS

Abstract

Background

In recent years, the incidence of early-onset pancreatic cancer (EOPC) has increased. Several studies comparing the survival of patients with EOPC to those with average-onset pancreatic cancer (AOPC) have reported mixed results. We aimed, therefore, to perform a meta-analysis summarizing the current evidence.

Methods

We searched the MEDLINE and EMBASE databases for relevant articles published through March 2024. Articles comparing the survival of patients with EOPC – defined as pancreatic ductal adenocarcinoma (PDAC) diagnosed at ≤ 50 years of age – and AOPC were included in the present meta-analysis. The primary outcome was the pooled adjusted hazard ratio (aHR), and the risk of bias analysis was performed using the Quality in Prognostic Factor Studies tool. The meta-analysis was performed using a random-effects model.

Results

A total of 17 studies were eligible for the primary analysis, the results of which indicated that patients with EOPC had a longer overall survival than those with AOPC (aHR = 0.80; 95% confidence interval [CI], 0.74–0.86; P < 0.001). The rate of distant metastasis was higher in EOPC than AOPC; however, patients with EOPC also received more treatments than those with AOPC.

Conclusions

Patients with EOPC had a better prognosis than those with AOPC. Clinicians must ensure that patients with PDAC receive early and appropriate treatment to improve their survival.

Keywords

Meta-analysis, Pancreatic neoplasms, Survival, Young adult

Introduction

As of 2022, pancreatic cancer is the 12th most common type of cancer and the 6th largest contributor of cancer-related mortality worldwide, with a relative 5-year survival rate of 12.5%.1 According to the Surveillance, Epidemiology, and End Results (SEER) database, the median age of patients diagnosed with pancreatic cancer is 70 years old2; however, the number of younger patients diagnosed with pancreatic cancer, termed early-onset pancreatic cancer (EOPC), is increasing.3

There is no consensus regarding the definition of EOPC as it pertains to age; however, it is largely used to describe patients who are ≤ 50 years of age when diagnosed with pancreatic cancer.47 Additionally, pancreatic cancer that is diagnosed at age < 45 years old is occasionally defined as very early-onset pancreatic cancer (VEOPC).8 EOPC accounts for 0.87–11.50% of pancreatic cancers, depending on the study population.9,10 Although EOPC occurs more often in males, the age-adjusted incidence rate increased significantly more in young females than their male counterparts.11 Several risk factors have been associated with EOPC, including heavy alcohol consumption, smoking, family history of pancreatic cancer, diabetes mellitus, obesity, and pancreatitis.12 Some studies also showed unique molecular profiles in patients with EOPC, such as a higher frequency of wild-type KRAS and higher mutation rates of CDKN2A, SMAD4, and FOXC2.13 Although the effects of these genomic alterations on tumor behavior are still unclear, some studies have shown that patients with EOPC often present with higher rates of distant metastasis.14

Studies investigating differences in survival times between patients with early-onset PDAC and those with average-onset PDAC (AOPC) have shown conflicting results. Several studies have shown that patients with EOPC have a better prognosis than those with AOPC4,15; however, some studies have shown that patients with EOPC have a worse survival than those with AOPC.9,14 Additionally, some studies did not find any significant difference in survival between patients with EOPC and those with AOPC.5,7 To the best of the authors’ knowledge, however, a meta-analysis on this topic has not yet been performed. In the present study, therefore, we conducted a meta-analysis of studies that compared the survival rates of patients with EOPC to those with AOPC, specifically focusing on pancreatic ductal adenocarcinoma (PDAC), which is the most common type of pancreatic cancer (approximately 90%).16

Methods

The present systematic review and meta-analysis was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) checklist.17

Inclusion and exclusion criteria

We used the PICOTS framework18 to define the review questions, as follows: Population = patients with PDAC; Index Prognostic Factor = EOPC; Comparator Prognostic Factor = adjusted for cancer stage/resectability status/tumor size; Outcome = Survival; Timing = age at diagnosis; Setting = all care settings. Based on the review question, the inclusion criteria were as follows: 1) studies that compared the overall survival between patients with EOPC and those with AOPC, although to maximize the number of studies included, if only cancer-specific survival were available, studies were still accepted; 2) studies that defined EOPC as patients who were diagnosed with PDAC at ≤ 50 years of age (although various definitions of EOPC are used in the relevant literature, we chose this cut-off because it was the most frequently used definition in the literature47,9,14,1924; by this definition, studies that used a cut-off of 45 or 40 years of age were also included, and the comparator group in each study was categorized as the AOPC group); and 3) survival analysis must be adjusted to the tumor stage (either by regression analysis or matching) – if the American Joint Committee on Cancer (AJCC) cancer stage25 was unavailable, we also accepted survival analysis, which was adjusted for tumor resectability or tumor size to maximize the number of studies included. The exclusion criteria were as follows: 1) studies with only abstracts available; 2) studies that did not present a hazard ratio and were inestimable from other values by the methods described by Tierney et al.26 and Hebert et al.27; and 3) studies that were not available in English.

Search strategy

Two independent reviewers searched the MEDLINE and EMBASE databases for articles published through March 2024. For MEDLINE, the following search terms were used: (early-onset pancreatic cancer [Title/Abstract]) OR ((young [Title/Abstract] AND pancreatic cancer [Title/Abstract])). For EMBASE, the following terms were used: ‘early-onset pancreatic cancer’:ab,ti OR (young:ab,ti AND ‘pancreatic cancer’:ab,ti). We also reviewed the reference lists of related papers to identify additional studies.

Data extraction

Two independent reviewers extracted the data from included studies using the Checklist for Critical Appraisal and Data Extraction for Systematic Reviews of Prognostic Factor Studies (CHARMS-PF).18 The following data were extracted: authors; year of study; study design; definition of EOPC and AOPC; number of subjects; period of recruitment; evaluation of survival; median follow-up; adjustment to other variables; hazard ratio; rate of distant metastasis; and proportion of subjects who received surgery, chemotherapy, or radiotherapy. Additionally, the risk of bias for each study was analyzed using the Quality in Prognostic Factor Studies (QUIPS) tool,28 which evaluates the following aspects: adequate study participation; study attrition; prognostic factor measurement; outcome measurement; adjustment for other prognostic factors; and statistical analysis and reporting. Permission has been obtained from the creator to use the QUIPS tool.

Statistical analysis

The Review Manager (RevMan) 5.3 program (The Nordic Cochrane Center, Copenhagen, Denmark)29 and R 4.3.2 program (R Core Team, Vienna, Austria)30 were used to perform the meta-analysis. The primary outcome was overall survival. The adjusted hazard ratio (aHR) for each study was used in the pooled analysis and presented as forest plots. If there was a study in which survival analysis was stratified based on cancer stage or resectability, multiple hazard ratios were first pooled into one value. If the aHR was not stated, it was estimated using the methods described by Tierney et al.26 and Hebert et al.27 If there was substantial heterogeneity between the studies, we used a random effects analysis to calculate the pooled aHR, otherwise, a fixed-effects analysis was used. Additionally, we performed a pooled hazard ratio analysis for cancer-specific survival (CSS), disease-free survival (DFS), progression-free survival (PFS), and recurrence-free survival (RFS).

We also performed sensitivity analyses, based on the type of survival analysis, age cutoff, presence of matching, regression analysis, published hazard ratio only, and adjustment for several covariates, as well as a subgroup analysis of the patients who underwent surgery. Publication bias was assessed using funnel plots, and Egger’s test was performed using ProMeta 3 (Internovi, Cesena, Italy).31 Additionally, we calculated the pooled risk ratios for the rates of distant metastasis (stage IV cancer) and treatment (surgery, chemotherapy, and radiotherapy).

Results

Study selection

The PRISMA study flow diagram is shown in Figure 1. A total of 522 records were initially obtained from MEDLINE, EMBASE, and the reference lists of the eligible studies, after the removal of duplicates, of which 46 were assessed for eligibility. Articles that only included patients with EOPC or used different age cutoffs for EOPC (e.g., age < 55, < 60, or < 70 years) were excluded. Table S1 shows a list of the excluded studies and the reasons for their exclusion. In total, 17 studies were included in the final analysis.

62fbb4e3-4af1-4d6e-aeaf-0307b91f610d_figure1.gif

Figure 1. PRISMA study flow diagram.

Study characteristics

Table 1 shows the characteristics of the 17 studies included in the present meta-analysis. The total number of patients with EOPC was 33,274 subjects, while that of those with AOPC was 563,198.

Table 1. Summary of included studies.

No.StudyDefinitions% of EOPC patients in populationNo. of EOPC patientsNo. of AOPC patientsPlace & period or recruitmentMedian follow-upAdjustment to survival analysisAdjusted HR (EOPC vs. AOPC)Median survival & survival rates (EOPC vs. AOPC)
1.Kang JS 2017EOPC = <45 y.o.; AOPC = 45 y.o.4.90%

  • - 34 (total, before PSM)

  • - 34 (after PSM)

  • - 665 (total, before PSM)

  • - 68 (after PSM)

South Korea, 2000–2014Not statedNo Cox regression, only PSM. PSM adjusted with patients' ASA score, AJCC stage, adjuvant chemotherapy and radiotherapy.Not stated

  • - Median OS: 17 months vs. 32 months; P = 0.970

  • - 5-year OS: 5.4% vs. 18.0%

2.Ansari D 2019EOPC = <50 y.o.; LOPC = ≥ 50 y.o.6.20%

  • - 3172 (after PSM)

  • - 3172 (after PSM)

USA, 2004–2016Not statedGender, tumor size, AJCC stage 7th edition, surgery, and chemotherapyaHR = 1.07 (95% CI 1.01–1.13; P = 0.015)

  • - Median survival: Not stated

  • - 5-year OS: 6.1% vs 8.6%, p = 0.003

  • - 5-year CSS: 6.7% vs 9.7%, p < 0.001

3.Saadat LV 2021EOPC = <50 y.o.; AOPC = >= 50 y.o.6.30%11161 (treated pts)92387 (treated pts)USA, 2004–201630.2 monthsNo Cox regression, although there were subgroup analyses based on treated and untreated patients, stage 0–2 disease, stage 3–4 disease, and time periodNot stated

  • - Median survival: Not stated

  • - 1-year OS for stage 0-2 disease: 72.4% (95%CI: 71.2%–73.7%) vs. 53.3% (95%CI: 52.9%–53.7%)

  • - 1-year OS for stage 3 disease: 47.6 (95%CI: 45.1%–50.0%) vs 37.8% (95%CI: 37.1%–38.4%)

  • - 1-year OS for stage 4 disease: 24.8% (95%CI: 23.8%–25.8%) vs 14.8% (95%CI: 14.5%–14.9%)

4.Dai D 2019EOPC = < 45 y.o. vs. older group2.50%138653932USA, 2004–?Not statedAge, sex, race, tumor location, surgery experience, tumor size, lymph node ratio, 6th AJCC TNM stage, grade, radiotherapy & chemotherapy experience, marital status

  • - aHR age < 45 y.o. vs. 45–59 y.o. = 0.93 (95% CI 0.88–0.98; P = 0.010)

  • - aHR age < 45 y.o. vs. 60–69 y.o. = 0.91 (95% CI 0.85–0.96; P = < 0.001)

  • - aHR age < 45 y.o. vs. 70–79 y.o. = 0.86 (95% CI 0.81–0.92; P = < 0.001)

  • - aHR age < 45 y.o. vs. >79 y.o. = 0.85 (95% CI 0.81–0.91; P = < 0.001)

Not stated
6.Piciucchi M 2015EOPC = ≤ 50 y.o. at diagnosis, AOPC = age > 50 y.o. at diagnosis8.50%25268Italy, 2006–2013Not statedTumor stage included, others unclearaHR = 0.7; (95% CI 0.4–1.1; p = 0.1)

  • - Median OS = 11 months vs. 9 months; P = 0.28

6.Tingstedt B 2011EOPC = ≤ 50 y.o. at diagnosis, AOPC = age > 50 y.o. at diagnosis5.70%3333Sweden, Jan 1993–Dec 2008Not statedNo Cox regression, but patients were matched with controls based on sex, resection, tumor size, chemotherapy and radiotherapyNot stated

  • - Median OS: 5.67 months vs. 8.00 months; P = 0.12

  • - 5-year OS: 3.3% vs. 0%

7.He J 2013EOPC = ≤ 45 y.o., LOPC = ≥ 70 y.o.7.90%75870USA, 1975–2009Not statedNo Cox regression, only subgroup analysis based on cancer stageNot stated

  • - Median OS: 19 months vs. 16 months; P = 0.007

  • - 5-year OS = 24% vs. 11%; P = 0.005

  • - 10-year OS = 17% vs. 3%, P < 0.001

8.Ordonez JE 2020EOPC = <50 y.o.; AOPC = ≥ 50 y.o. at diagnosis5.90%12137194925USA, 2004–2013Not statedAge, sex, race/ethnicity, comorbidities, insurance status, tumor size, anatomic location, tumor grade/differentiation, lymph node status, AJCC stage, presence of lymphovascular invasion, and receipt of surgery, chemotherapy, or radiation0.867 (95% CI 0.85–0.88)

  • - Median OS: 9.2 months vs. 6.0 months; P < 0.001

9.Beeghly-Fadiel A 2016EOPC = <50 y.o.; AOPC = ≥50 y.o. at diagnosis11.50%1181282USA, 1988─2013Not statedAge, race, year of diagnosis, AJCC stage, tumor location, treatment received, multiple malignancies, family history of pancreatic cancer0.82 (95% CI 0.67─1.00)

  • - - Median OS: 9.36 months vs. 8.04 months; P = 0.403

10.Whitley A 2023EOPC = ≤ 50 y.o. at diagnosis, AOPC = age > 50 y.o. at diagnosis7.00%132417564Czech Republic, 1985─2015Not statedNo Cox regression, but had subgroup analysis based on the stage of cancerNot stated

  • - Median OS: 5.9 months vs. 4.5 months; P < 0.001

  • - 1-year OS: 28.4% vs. 22.6%; P < 0.001

  • - 2-year OS: 15.3% vs. 10.1%; P < 0.001

  • - 3-year OS: 11.4% vs. 6.6%; P < 0.001

  • - 5-year OS: 8.2% vs. 4.0%; P < 0.001

11.Castet F 2023EOPC = ≤ 50 y.o. at diagnosis, AOPC = age ≥ 70 y.o. at diagnosisNot stated139141Spain, 2010─202254.8 monthsSex, history of diabetes, tobacco history, alcohol intake, clinical stage, tumor location, ECOG performance status (ECOG-PS), CA19.9 levels, albumin levels, and neutrophil-to-lymphocyte ratio (NLR)0.87 (95% CI 0.65─1.16; P = 0.33)

  • - Median OS: 18.7 months vs. 17.6 months; P = 0.75

12.Zironda A 2023EOPC = ≤ 50 y.o. at diagnosis, AOPC = age > 50 y.o. at diagnosis5.70%651068USA, Jan 2011─Dec 202122.4 monthsOnset of PDAC, age, race, sex, ASA, diabetes, elevated Ca 19-9, neoadjuvant therapy, adjuvant therapy, minimally invasive surgery approach, vascular resection, major complication, IPMN pathology, tumor size, grade, lymph node involvement, R0 resection0.93 (95% CI 0.64─1.33; P = 0.68)

  • - Median OS: 30.6 months vs. 31.0 months

  • - 1-year OS: 73.3% vs. 79.5%

  • - 3-year OS: 43.9% vs. 43.9%

  • - 5-year OS: 33.0% vs. 31.0%

13.Takeda T 2022EOPC = ≤ 50 y.o. at diagnosis, AOPC = age > 50 y.o. at diagnosis8.00%1271519Japan, Jan 2010─Aug 2019Not stated.No Cox regression, but had subgroup analysis based on resectability of cancerNot stated

  • - Median OS: 16.9 months vs. 17.1 months; P = 0.565

14.Ren S 2023EOPC = < 50 y.o. at diagnosis, AOPC = age ≥ 50 y.o. at diagnosis6.90%7632278USA, 2004─2018Not statedSex, race, site, tumor differentiation, TNM stage and treatment patternsNot stated

  • - Median OS: 9 months vs. 8 months; P = 0.002

  • - 1-year OS: 38.4% vs. 36.8%

  • - 3-year OS: 11.1% vs. 10.1%

  • - 5-year OS: 6.9% vs. 5.8%

15.Ramai D 2021EOPC = ≤ 40 y.o. at diagnosis, AOPC = age > 40 y.o. at diagnosis0.87%1181134919USA, 1975─2016Not statedAge, sex, race, tumor grade, stage, T status, N status, primary tumor site, no. of lymph node examined, no. of positive lymph nodes, receipt of surgery, chemotherapy, or radiation0.485 (95% CI 0.422–0.557, P < 0.001)

  • - Median OS: 7.0 months vs. 6.0 months; P < 0.001

16.Wang H 2020EOPC = ≤ 40 y.o. at diagnosis, AOPC = age > 40 y.o. at diagnosis1.12%142257201USA, 2004─2015Not statedRace, gender, year of diagnosis, pathological grade, AJCC stage, historic stage, tumor location

  • - aHR age 20–40 vs. 40–60 = 0.54 (95% CI 0.50–0.58; P < 0.001)

  • - aHR age 20–40 vs. 60–80 = 0.45 (95% CI 0.42–0.49; P < 0.001)

  • - aHR age 20–40 vs. >80 = 0.30 (95% CI 0.28–0.33; P < 0.001)

  • - Median CSS age 20–40 vs. age 40–60 vs. age 60–80 vs. age >80 = 36.0 months vs. 10.0 months vs. 8.0 months vs. 4.0 months

  • - 5-year CSS age 20–40 vs. age 40–60 vs. age 60–80 vs. age >80: 44.7% vs. 16.9% vs. 13.8% vs. 8.7%

17.Mendis S 2024EOPC = ≤ 50 y.o. at diagnosis, AOPC = age > 50 y.o. at diagnosis6.70%1121571Australia, New Zealand, Singapore, Jan 2016–Dec 202123.6 monthsNo Cox regression, but has subgroup analysis based on tumor resectability

  • - aHR locally advanced = 0.47 (95% Cl 0.32–0.69; P = 0.005)

  • - aHR metastatic = 0.66 (95% Cl 0.48–0.89; P =0.025)

  • - Median OS: 23.4 months vs 10.3 months

  • - P < 0.001

Risk of bias

Table 2 shows the risk of bias for the 17 studies included in the present meta-analysis.

Table 2. Risk of bias of included studies.

No.StudyStudy participationStudy attritionPrognostic factor measurementOutcome measurementAdjustment for other prognostic factorsStatistical analysis & reporting
1.Kang JS 2017ModerateModerateLowLowLowModerate
2.Ansari D 2019LowLowLowLowLowLow
3.Saadat LV 2021ModerateLowLowLowModerateModerate
4.Dai D 2019LowLowLowLowLowLow
5.Piciucchi M 2015ModerateModerateLowLowModerateLow
6.Tingstedt B 2011LowModerateLowLowLowModerate
7.He J 2013LowLowLowLowModerateModerate
8.Ordonez JE 2020LowLowLowLowLowLow
9.Beeghly-Fadiel A 2016LowLowLowLowLowLow
10.Whitley A 2023LowLowLowLowModerateModerate
11.Castet F 2023LowLowLowLowLowLow
12.Zironda A 2023LowLowLowLowLowLow
13.Takeda T 2022LowLowLowLowModerateModerate
14.Ren S 2023LowLowLowLowLowModerate
15.Ramai D 2021ModerateLowLowLowLowModerate
16.Wang H 2020LowLowLowLowLowLow
17.Mendis S 2024LowLowLowLowModerateLow

Meta-analysis

Overall survival (OS)

Figure 2 shows the forest plot of the OS analysis of the studies included in the present meta-analysis. The patients with EOPC had a better OS than those with AOPC (aHR = 0.80; 95% confidence interval [CI], 0.74–0.86; P < 0.001). The range of median survival for EOPC subjects was 5.7─36.0 months, while the range of median survival for AOPC patients was 4.0─32.0 months.

62fbb4e3-4af1-4d6e-aeaf-0307b91f610d_figure2.gif

Figure 2. Forest plot of overall survival analysis between EOPC and AOPC patients.

The sensitivity analysis is shown in Table 3.

Table 3. Sensitivity analysis for the pooled overall survival of included studies.

Sensitivity analysisNo. of studiesPooled Adjusted Hazard Ratio (95% CI)
Only published adjusted hazard ratio70.80 (95% CI 0.68─0.96, P = 0.01)
Only studies with ‘overall survival’ as the primary outcome150.81 (95% CI 0.73─0.89, P < 0.001)
<50 years old (EOPC) cut off120.86 (95% CI 0.79─0.93, P = 0.0003)
<45 years old (EOPC) cut off30.88 (95% CI 0.85─0.91, P < 0.001)
<40 years old (EOPC) cut off20.47 (95% CI 0.42─0.54, P < 0.001)
<50 years old (EOPC) vs. >50 years old (AOPC) only110.86 (95% CI 0.79─0.93, P = 0.0003)
<45 years old (EOPC) vs. >45 years old (AOPC) only20.88 (95% CI 0.85─0.91, P < 0.001)
Adjusted for treatment received80.82 (95% CI 0.74─0.92, P < 0.001)
Adjusted for cancer stage120.80 (95% CI 0.73─0.87, P < 0.001)
Adjusted for comorbidities10.87 (95% CI 0.85─0.88, P < 0.001)
Studies with propensity-score based method40.95 (95% CI 0.81─1.12, P = 0.56)
Studies with Cox regression method90.79 (95% CI 0.70─0.88, P < 0.001)

The funnel plot for OS analysis is shown in Figure S1. Egger’s test showed no significant publication bias (P = 0.227).

We also performed a pooled analysis of studies that included other types of survival analyses. Pooled CSS analysis (n = 4), as seen in Figure S2, showed that patients with EOPC had a better CSS than those with AOPC (HR = 0.85; 95% CI, 0.72–1.00; P = 0.05). Pooled RFS analysis (n = 4), as seen in Figure S3, showed that patients with EOPC had a similar RFS to those with AOPC (HR = 1.10; 95% CI, 0.78–1.54; P = 0.60). The pooled PFS (n = 3), as seen in Figure S4, also showed that patients with EOPC had a similar PFS to those with AOPC (HR = 0.84; 95% CI, 0.61–1.17; P = 0.30). Only one study reported DFS, which showed that patients with EOPC had a worse DFS than those with AOPC (HR = 2.40; 95% CI, 1.13–5.10; P = 0.02).32

Overall survival in patients undergoing surgery

Figure 3 shows the forest plot for studies that performed subgroup OS analyses in patients undergoing surgery (n = 9), the result of which showed that patients with EOPC who underwent surgery had a similar OS to those with AOPC who underwent surgery (aHR = 0.95; 95% CI, 0.84–1.08; P = 0.44).

62fbb4e3-4af1-4d6e-aeaf-0307b91f610d_figure3.gif

Figure 3. Forest plot of subgroup overall survival analysis between EOPC and AOPC patients who received surgery.

Distant metastasis

Figure S5 shows the pooled analysis of the risk ratio (RR) of distant metastasis between patients with EOPC and those with AOPC. Twelve studies were included in the pooled analysis, the results of which showed that patients with EOPC had an increased risk of distant metastasis (stage IV) than those with AOPC (RR = 1.08; 95% CI, 1.03–1.13; P = 0.001).

Treatments received

Surgery

Figure S6 shows the pooled analysis of the RR of the rate of surgery between patients with EOPC and those with AOPC, the results of which showed that patients with EOPC underwent more surgeries than those with AOPC (RR = 1.22; 95% CI, 1.13–1.32; P < 0.001).

Chemotherapy

Figure S7 shows the pooled analysis of the RR of the rate of chemotherapy between patients with EOPC and those with AOPC, the results of which showed that patients with EOPC received more chemotherapy than those with AOPC (RR = 1.31; 95% CI, 1.25–1.37; P < 0.001).

Radiotherapy

Figure S8 shows a pooled analysis of the RR of the rate of radiotherapy between patients with EOPC and those with AOPC, the results of which showed that patients with EOPC underwent more radiotherapy than those with AOPC (RR = 1.35; 95% CI, 1.32–1.38; P < 0.001).

Discussion

The relationship between age at diagnosis and the survival of patients with cancer is complex. Some studies have shown that early-onset breast, lung, central nervous system, and soft tissue cancers are associated with poor prognosis.33,34 Other studies, however, have shown that patients with early-onset cancer had a better OS than those with late-onset cancer, such as colorectal cancer.35 The results of our meta-analysis fall in line with the latter, showing that EOPC patients had better prognosis than AOPC patients. Our findings are in line with the results of most previous studies. For example, Beeghly-Fadiel et al.9 showed that patients with EOPC had a better OS than those with AOPC, independent of other factors. They also showed that the mortality rate increased significantly after the age of 60 years in patients with EOPC. A study by Ordonez et al.14 showed similar results. Although patients with EOPC presented with several risk factors that are typically associated with worse survival (e.g., more advanced stage, male sex, and non-caput tumor), they still had a better OS than patients with AOPC.

Several other studies, however, have reported contradictory results. Ansari et al.4 analyzed 72,906 patients with PDAC from the SEER registry, and after propensity score matching, found that patients with EOPC had a shorter CSS than those with AOPC. This result was true even after controlling for other factors, such as cancer stage and treatment received by the patients. They also found that patients with EOPC were also more often diagnosed at more advanced AJCC stages and received more treatments (surgery, radiotherapy, and chemotherapy) than patients with AOPC. Another registry-based study in Japan also found that younger patients had worse survival rates than older patients. Similarly, the aforementioned study showed that younger patients were often diagnosed at more advanced stages than older patients; however, they found that younger patients underwent fewer surgeries and achieved fewer R0 resections than older patients. When subgroup analysis of resected patients was performed, there was no difference in the survival rates between younger and older patients.15 The aforementioned study was not included in the pooled analysis, however, because the survival analysis was not adjusted for cancer stage.

The pooled analysis in the present study also showed that patients with EOPC had a higher rate of distant metastasis than those with AOPC, a phenomenon which was also observed in previous studies. For example, Tingstedt et al.7 found a higher proportion of distant metastasis in patients with EOPC than in those with AOPC. Eguchi et al.15 found that patients with EOPC had a larger tumor size, liver metastasis, and peritonitis carcinomatosa than those with AOPC. It is still unclear why patients with EOPC are more often diagnosed at an advanced cancer stage compared to patients with AOPC. One potential explanation for this might be the underdiagnosis of cancer in younger patients, as clinicians may be less likely to diagnose rare pathologies in younger patients, particularly in the early stages of the disease. Additionally, younger patients are more likely to present to the hospital at a later stage of the disease, due to a reluctance to seek care early.36 Some studies have hypothesized that patients with EOPC may have a more aggressive tumor phenotype than patients with AOPC due to differences in their molecular profiles.37,38

Several studies have compared the molecular profiles of EOPC and AOPC, with mixed results. Bergmann et al.37 investigated the molecular characteristics of 7 patients with PDAC aged ≤ 40 years old, and found that all of the patients exhibited SMAD4 inactivation, which was associated with more aggressive tumors. Surprisingly, they also found that most patients had wild-type KRAS, which is unusual, as KRAS mutations are commonly found in patients with PDAC (90%).16 Wild-type KRAS was also associated with other targetable alterations, such as mismatch repair deficiency.38 In a recent preprint, Ogobuiro et al.39 showed that patients with EOPC with wild-type KRAS tumors had fewer TP53 mutations. Instead, carcinogenesis in EOPC is more likely driven by NRG1 and MET fusions. BRAF fusion was observed only in patients with AOPC with wild-type KRAS. In a subgroup analysis of patients with wild-type KRAS, the patients with EOPC had a better prognosis than those with AOPC; however, there was no difference in the survival of any patients with mutant KRAS. These molecular characteristics might explain the different results of prognostic studies comparing patients with EOPC and those with AOPC. Other studies have also shown a higher rate of mutations in several genes in patients with EOPC compared to patients with AOPC, such as CDKN2A, FOXC2, and PI3KCA.40,41

Whether younger patients had a higher prevalence of pathogenic germline variants (PGVs) than older patients remains unclear. Bannon et al.42 found that patients with EOPC had a higher prevalence of PGVs (most commonly BRCA1/2 and MMR) than patients with AOPC, which was especially true for patients < 42 years old (OR = 4.17; 95% CI, 1.42–11.84; P= 0.011). Castet et al.19 found that 22% of patients from the EOPC group and 13% from the AOPC group had PGVs, the most common of which was BRCA2. However, TP53, PMS2, and MSH6 PGVs were only found in the EOPC group. Additionally, patients with PGVs had a better OS than those without PGVs, independent of other factors. In contrast, Raffene et al.43 found no significant molecular profile differences between the EOPC and AOPC. It is possible that only a certain subset of EOPC patients have distinct molecular profiles than AOPC patients. Intra-tumoral (variability across individual cell populations within a biopsy site) and inter-tumoral heterogeneity (variability across individual cell populations between the primary and the metastatic site) may also be present, which are important confounders in genomic studies.41

Despite showing that patients with EOPC had a higher rate of distant metastasis, the results of the present meta-analysis also showed that patients with EOPC received more treatments than those with AOPC, which might explain why patients with EOPC had longer survival times than those with AOPC, even though they were more often diagnosed at a more advanced stage. This hypothesis was corroborated by a subgroup analysis of patients who underwent surgery, the results of which showed no significant difference in survival between the two groups. This phenomenon has been universally observed in other studies. Saadat et al.6 studied the differences in treatment utilization patterns between patients with EOPC and those with AOPC in the United States. They found that overall, patients with EOPC received more multimodal treatment regimens than those with AOPC, regardless of the cancer stage; therefore, they hypothesized that younger patients would be more willing to seek care, more likely to have private health insurance, have better access to tertiary healthcare centers, and be more fit to undergo treatment. Clinicians were also more willing to prescribe intensive treatments to younger patients because of their longer life expectancies compared to older patients; however, a high percentage of patients with EOPC and AOPC (19% and 39%, respectively) did not receive any treatment. Those who received no treatment tended to be non-White females with no private health insurance, less income, and lower levels of education, suggesting the vital role of the social determinants in the health of patients with PDAC. It is also important to note that most of these studies were conducted in developed countries, whereas patients with EOPC in developing countries may face more barriers to treatment, primarily due to financial hurdles. Younger patients with cancer may have no or inadequate health insurance coverage, limited financial assets, and significant work interruptions, leading to high financial strain.44 Therefore, patients with EOPC in developing countries may have different treatment utilization patterns than those in developed countries.

The present study has several limitations. First, we only included studies written in English, which may have increased publication bias. Second, there was also substantial heterogeneity between the included studies, possibly due to differences in the age cutoffs for EOPC, study time frames that might have lead to different treatment protocols, and the inclusion of covariates in the survival analysis. Therefore, we performed several sensitivity analyses that yielded similar conclusions. Third, the retrospective design of the included studies also means that some data, such as the specific chemotherapeutic agents used and genetic data, may be difficult to obtain. The present study does, however, have several strengths. First, to the best of the authors’ knowledge, this is the first meta-analysis to compare the survival of patients with EOPC to those with AOPC. Finally, we used multiple statistical methods21,27 to estimate the aHR of several studies to maximize study inclusion and minimize publication bias.

Ethics and consent

Ethical approval and consent were not required.

Comments on this article Comments (0)

Version 1
VERSION 1 PUBLISHED 28 Aug 2024
Comment
Author details Author details
Competing interests
Grant information
Copyright
Download
 
Export To
metrics
Views Downloads
F1000Research - -
PubMed Central
Data from PMC are received and updated monthly.
- -
Citations
CITE
how to cite this article
Renaldi K and William A. The Association between Early-Onset Pancreatic Ductal Adenocarcinoma and Patients Survival: A Systematic Review and Meta-Analysis [version 1; peer review: 2 approved]. F1000Research 2024, 13:976 (https://doi.org/10.12688/f1000research.153743.1)
NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.

Open Peer Review

Current Reviewer Status: ?
Key to Reviewer Statuses VIEW
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
Version 1
VERSION 1
PUBLISHED 28 Aug 2024
Views
10
Cite
Reviewer Report 30 Sep 2024
Stefania Bunduc, Centre for Translational Medicine, Semmelweis University, Budapest, Hungary;  Carol Davila University of Medicine and Pharmacy, Bucharest, Romania 
Approved
VIEWS 10
The authors have performed a systematic review and meta analysis evaluating the prognosis differences between early (<= 50 years of age) and average (> 50 years old) onset pancreatic cancer patients.

The methodology is sound, reporting is ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Bunduc S. Reviewer Report For: The Association between Early-Onset Pancreatic Ductal Adenocarcinoma and Patients Survival: A Systematic Review and Meta-Analysis [version 1; peer review: 2 approved]. F1000Research 2024, 13:976 (https://doi.org/10.5256/f1000research.168677.r322276)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Views
11
Cite
Reviewer Report 11 Sep 2024
Yan Wisnu Prajoko, Department of Surgical Oncology, Diponegoro University, Semarang, Indonesia 
Approved
VIEWS 11
1. The topic of this article is quite interesting and updated. because reviewing the prevalence of early onset pancreatic cancer which has increased quite a bit recently, both in developing countries and especially in developed countries.
 
2. ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Prajoko YW. Reviewer Report For: The Association between Early-Onset Pancreatic Ductal Adenocarcinoma and Patients Survival: A Systematic Review and Meta-Analysis [version 1; peer review: 2 approved]. F1000Research 2024, 13:976 (https://doi.org/10.5256/f1000research.168677.r318420)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
  • Author Response 13 Sep 2024
    Kaka Renaldi, Universitas Indonesia, Depok, Indonesia
    13 Sep 2024
    Author Response
    Thank you for the kind comment and for taking time to review our paper.
    Competing Interests: No competing interest
COMMENTS ON THIS REPORT
  • Author Response 13 Sep 2024
    Kaka Renaldi, Universitas Indonesia, Depok, Indonesia
    13 Sep 2024
    Author Response
    Thank you for the kind comment and for taking time to review our paper.
    Competing Interests: No competing interest

Comments on this article Comments (0)

Version 1
VERSION 1 PUBLISHED 28 Aug 2024
Comment
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Sign In
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email us for further assistance.
Server error, please try again.